Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 11/06/23
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical TrialGlobeNewsWire • 08/22/23
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate CancerGlobeNewsWire • 08/22/23
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/10/23
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 08/03/23
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor ConferencesAccesswire • 05/24/23
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesAccesswire • 05/15/23
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual CongressAccesswire • 05/12/23
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference CallAccesswire • 05/08/23
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual CongressAccesswire • 05/08/23
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023Accesswire • 04/18/23
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateAccesswire • 03/23/23
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference CallAccesswire • 03/16/23
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023Accesswire • 03/15/23